Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.17 USD
+0.04 (3.54%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.15 -0.02 (-1.71%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 81 - 100 ( 274 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
OASIS Trial Completes Cohort 2 Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
CLS-AX/wet AMD: Cohort 2 Dosed, Readout Expected by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
CLS-AX Data in Wet AMD Expected by YE & Adding to Multiple 2H21 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Expands XIPERE Licensing Agreement with Arctic Vision
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q2: XIPERE PDUFA on Oct 30, All Eyes on OASIS Cohort 2 Results by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update - Key Value-Driving 2H21 Catalysts, Recommend Buying Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE Regulatory Approval Near-Term; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Disrupting Drug Delivery to the Eye; Initiating at Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Adding CLS-AX to Model Due to Early Efficacy in wAMD & Raising PT to $15
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Cohort 1 Data Establishes Safety, Hints at Efficacy for CLS-AX/ wAMD; Raising PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L